Posted by Michael Wonder on 27 Feb 2025
BlueRock Therapeutics receives FDA fast track designation for OpCT-001 for the treatment of primary photoreceptor diseases
27 February 2025 - First iPSC-derived investigational cell therapy, OpCT-001, to be clinically tested for treating primary photoreceptor diseases.
Bayer and BlueRock Therapeutics LP today announced that the US FDA has granted fast track designation for OpCT-001, an investigational induced pluripotent stem cell derived cell therapy for the treatment of primary photoreceptor diseases.
